Novel aromatase inhibitors by structure-guided design.

Human cytochrome P450 aromatase catalyzes with high specificity the synthesis of estrogens from androgens. Aromatase inhibitors (AIs) such as exemestane, 6-methylideneandrosta-1,4-diene-3,17-dione, are preeminent drugs for the treatment of estrogen-dependent breast cancer. The crystal structure of human placental aromatase has shown an androgen-specific active site. By utilization of the structural data, novel C6-substituted androsta-1,4-diene-3,17-dione inhibitors have been designed. Several of the C6-substituted 2-alkynyloxy compounds inhibit purified placental aromatase with IC(50) values in the nanomolar range. Antiproliferation studies in a MCF-7 breast cancer cell line demonstrate that some of these compounds have EC(50) values better than 1 nM, exceeding that for exemestane. X-ray structures of aromatase complexes of two potent compounds reveal that, per their design, the novel side groups protrude into the opening to the access channel unoccupied in the enzyme-substrate/exemestane complexes. The observed structure-activity relationship is borne out by the X-ray data. Structure-guided design permits utilization of the aromatase-specific interactions for the development of next generation AIs.

[1]  Yate-Ching Yuan,et al.  Molecular basis for the aromatization reaction and exemestane-mediated irreversible inhibition of human aromatase. , 2007, Molecular endocrinology.

[2]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[3]  A. Brodie,et al.  Aromatase, aromatase inhibitors, and breast cancer , 2011, The Journal of Steroid Biochemistry and Molecular Biology.

[4]  J. Kellis,et al.  Purification and characterization of human placental aromatase cytochrome P-450. , 1987, The Journal of biological chemistry.

[5]  D. Ghosh,et al.  Motion and Flexibility in Human Cytochrome P450 Aromatase , 2012, PloS one.

[6]  R. Brueggemeier.  Update on the use of aromatase inhibitors in breast cancer , 2006, Expert opinion on pharmacotherapy.

[7]  Giulio Rastelli,et al.  Structure-based design of potent aromatase inhibitors by high-throughput docking. , 2011, Journal of medicinal chemistry.

[8]  E. Simpson,et al.  Functional domains of human aromatase cytochrome P450 characterized by linear alignment and site-directed mutagenesis. , 1993, Molecular endocrinology.

[9]  K. Podratz,et al.  Aromatase inhibitors in the treatment of recurrent ovarian granulosa cell tumors: Brief report and review of the literature , 2012, The journal of obstetrics and gynaecology research.

[10]  N. Harada,et al.  Core glycosylation of cytochrome P-450(arom). Evidence for localization of N terminus of microsomal cytochrome P-450 in the lumen. , 1993, The Journal of biological chemistry.

[11]  Y. Ito,et al.  Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. , 1994, Endocrine reviews.

[12]  W. Miller,et al.  Minireview: regulation of steroidogenesis by electron transfer. , 2005, Endocrinology.

[13]  E. A. Thompson,et al.  The involvement of human placental microsomal cytochrome P-450 in aromatization. , 1974, The Journal of biological chemistry.

[14]  H. Ikeda,et al.  Crystal Structures of Cytochrome P450 105P1 from Streptomyces avermitilis: Conformational Flexibility and Histidine Ligation State , 2008, Journal of bacteriology.

[15]  Chang-Tong Yang,et al.  Development of Intravascular Contrast Agents for MRI Using Gadolinium Chelates , 2011, ChemMedChem.

[16]  Thompson Ea,et al.  The Involvement of Human Placental Microsomal Cytochrome P-450 in Aromatization , 1974 .

[17]  J. Johnston.  Aromatase inhibitors. , 2020, Critical reviews in biochemistry and molecular biology.

[18]  B. Potter,et al.  Aromatase and Dual Aromatase-Steroid Sulfatase Inhibitors from the Letrozole and Vorozole Templates , 2011, ChemMedChem.

[19]  Yate-Ching Yuan,et al.  Molecular basis for the interaction of four different classes of substrates and inhibitors with human aromatase. , 2008, Biochemical pharmacology.

[20]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[21]  N. Yoshida,et al.  Purification of human placental aromatase cytochrome P-450 with monoclonal antibody and its characterization. , 1991, Biochemistry.

[22]  W. Pangborn,et al.  X-ray structure of human aromatase reveals an androgen-specific active site , 2010, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  P. Labute.  Protonate3D: Assignment of ionization states and hydrogen coordinates to macromolecular structures , 2008, Proteins.

[24]  S. Bulun,et al.  Medical Therapies: Aromatase Inhibitors , 2012 .

[25]  D. Flockhart,et al.  Inhibition of drug metabolizing cytochrome P450s by the aromatase inhibitor drug letrozole and its major oxidative metabolite 4,4′-methanol-bisbenzonitrile in vitro , 2009, Cancer Chemotherapy and Pharmacology.

[26]  Wolfgang Eiermann,et al.  An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrozole, letrozole, and exemestane , 2002, Cancer.

[27]  D. Ghosh,et al.  Higher order organization of human placental aromatase , 2011, Steroids.

[28]  W. Pangborn,et al.  Structural basis for androgen specificity and oestrogen synthesis in human aromatase , 2009, Nature.

[29]  E. Simpson,et al.  A three‐dimensional model of aromatase cytochrome P450 , 1995, Protein science : a publication of the Protein Society.

[30]  K. Korzekwa,et al.  Mutagenesis study at a postulated hydrophobic region near the active site of aromatase cytochrome P450. , 1994, The Journal of biological chemistry.

[31]  L. Perey.  [Aromatase inhibitors in the treatment of breast cancer]. , 2000, Revue medicale de la Suisse romande.

[32]  P. Lombardi,et al.  6-Methylenandrosta-1,4-diene-3,17-dione (FCE 24304): a new irreversible aromatase inhibitor. , 1988, Journal of steroid biochemistry.

[33]  Tudor I. Oprea,et al.  Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen , 2007, Molecular Cancer Therapeutics.

[34]  Takashi Suzuki,et al.  Suppression of estrogen actions in human lung cancer , 2011, Molecular and Cellular Endocrinology.

[35]  T. Darden,et al.  Structural flexibility and functional versatility of mammalian P450 enzymes , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[36]  E. J. Sorensen,et al.  Classical carbonyl reactivity enables a short synthesis of the core structure of acutumine , 2007 .

[37]  A. Atilgan,et al.  Direct evaluation of thermal fluctuations in proteins using a single-parameter harmonic potential. , 1997, Folding & design.

[38]  Stefano Alcaro,et al.  New structure-activity relationships of A- and D-ring modified steroidal aromatase inhibitors: design, synthesis, and biochemical evaluation. , 2012, Journal of medicinal chemistry.

[39]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[40]  B. Kacsoh,et al.  Structural basis for the selective inhibition of human 3β-hydroxysteroid dehydrogenase 1 in human breast tumor MCF-7 cells , 2009, Molecular and Cellular Endocrinology.

[41]  P. Souček,et al.  Flexibility and stability of the structure of cytochromes P450 3A4 and BM-3. , 2000, European journal of biochemistry.